ENPP1 processes protein ADP-ribosylation *in vitro*

Luca Palazzo1†, Casey M. Daniels2*, Joanne E. Nettleship3,4, Nahid Rahman3,4, Robert Lyle McPherson2, Shao-En Ong6, Kazuki Kato6, Osamu Nureki6, Anthony K. L. Leung2,7 and Ivan Ahel1

1 Sir William Dunn School of Pathology, University of Oxford, UK
2 Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
3 OPPF-UK, The Research Complex at Harwell, Rutherford Appleton Laboratory, Harwell Oxford, UK
4 Division of Structural Biology, Henry Wellcome Building for Genomic Medicine, University of Oxford, UK
5 Department of Pharmacology, University of Washington, Seattle, WA, USA
6 Department of Biophysics and Biochemistry, Graduate School of Science, The University of Tokyo, Japan
7 Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

ADP-ribosylation is a conserved post-translational protein modification that plays a role in all major cellular processes, particularly DNA repair, transcription, translation, stress response and cell death. Hence, dysregulation of ADP-ribosylation is linked to the physiopathology of several human diseases including cancers, diabetes and neurodegenerative disorders. Protein ADP-ribosylation can be reversed by the macrodomain-containing proteins PARG, TARG1, MacroD1 and MacroD2, which hydrolyse the ester bond known to link proteins to ADP-ribose as well as consecutive ADP-ribose subunits; targeting this bond can thus result in the complete removal of the protein modification or the conversion of poly(ADP-ribose) to mono(ADP-ribose). Recently, proteins containing the NUDIX domain – namely human NUDT16 and bacterial RppH – have been shown to process *in vitro* protein ADP-ribosylation through an alternative mechanism, converting it into protein-conjugated ribose-5′-phosphate (R5P, also known as pR). Though this protein modification was recently identified in mammalian tissues, its physiological relevance and the mechanism of generating protein phosphoribosylation are currently unknown. Here, we identified ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) as the first known mammalian enzyme lacking a NUDIX domain – namely human NUDT16 and bacterial RppH – have been shown to process *in vitro* protein ADP-ribosylation through an alternative mechanism, converting it into protein-conjugated ribose-5′-phosphate (R5P, also known as pR). Though this protein modification was recently identified in mammalian tissues, its physiological relevance and the mechanism of generating protein phosphoribosylation are currently unknown. Here, we identified ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) as the first known mammalian enzyme lacking a NUDIX domain to generate pR from ADP-ribose on modified proteins *in vitro*. Thus, our data show that at least two enzyme families – Nudix and ENPP/NPP – are able to metabolize protein-conjugated ADP-ribose to pR in *in vitro*, suggesting that pR exists and may be conserved from bacteria to mammals. We also demonstrate the utility of ENPP1 for converting protein-conjugated mono(ADP-ribose) and poly(ADP-ribose) into mass spectrometry-friendly pR tags, thus facilitating the identification of ADP-ribosylation sites.

**Abbreviations**

ADPr, ADP-ribose; ARH, ADP-ribosylhydrolase; ARTC, ADP-ribosyltransferase cholera toxin-like; ARTs, ADP-ribosyltransferases; ECM, extracellular matrix; ENPP2-1-8xHis, ENPP2-1 chimera containing C-terminal 8xHistidine tag; ENPP2-1-T, ENPP2-1 chimera purified by TARGET tag; ENPP, ectonucleotide pyrophosphatase/phosphodiesterase; MAR, mono(ADP-ribose); MARylation, mono(ADP-ribosylation); MS, mass spectrometry; NAD, nicotinamide adenine dinucleotide; NPP, nucleotide pyrophosphatase/phosphodiesterase; PARG, PAR glycohydrolase; PAR, poly(ADP-ribose); PARPs, poly(ADP-ribose) polymerases; PARylation, poly(ADP-riboseylation); pR, ribose-5′-phosphate; PRAMP, phosphoribosyl-AMP; PTM, post-translational modification; SVP, snake venom phosphodiesterase; TARG1, terminal ADP-ribose glycohydrolase; TLC, thin layer chromatography.
**Introduction**

Protein ADP-ribosylation is a conserved post-translational modification (PTM) involved in the regulation of many cellular pathways in both eukaryotes and prokaryotes [1–4]. There are several enzyme classes of protein ADP-ribosyltransferases (ARTs) that are all able to transfer an ADP-ribose (ADPr) group from β-nicotinamide adenine dinucleotide (β-NAD) onto a specific protein acceptor with release of nicotinamide [1,2]. Some of the described protein ART families are the bacterial dinitrogen reductase ADP-ribosyltransferases (DraTs), poly(ADP-ribose) polymerases (PARPs), ART cholera toxin-like (ARTCs) and sirtuins [1,4–11]. In eukaryotes, the ARTCs are mostly extracellular proteins and may control immune responses [6–9]. Sirtuins are primarily known as protein deacetylases, but some of them can ADP-ribosylate protein targets [10,11].

Among ART enzymes, PARPs are the most studied. In humans, 17 members have been identified [1]. They are intracellular proteins involved in many cellular processes, such as DNA damage repair, transcription, cell cycle progression, unfolded protein response, trafficking, mitosis, cell death and RNA metabolism [1,3,4,9,12–16]. The majority of human ARTs, such as all the ARTC family members, sirtuins and 11 out of the 17 human PARPs, are able to transfer only a single ADP-ribose subunit (mono(ADP-ribose), or MAR) to target proteins [1,17,18], most commonly on acidic residues, such as aspartic and glutamic acid, and arginine residues [1,7,9,19–21]. However, ADP-ribosylation has also been described for other amino acids, such as serines, threonines, phosphoserines, cysteines, lysines and diphthamides (reviewed in Ref. [20]). Several PARP family members (e.g. PARP1, PARP2 and tankyrases) are able to produce long poly(ADP-ribose) (PAR) chains by adding further repeating ADPr units (up to 200 units in length) via unique O-glycosidic ribose–ribose bonds [1,15,22–24].

Protein ADP-ribosylation is a tightly controlled PTM [24,25]: once the cellular response induced by protein modification has been achieved, ADP-ribosylation signalling has to be silenced properly and in a timely manner, and the ADPr subsequently recycled [1,4,26]. PAR glycohydrolase (PARG) is the most characterized enzyme in humans for PAR hydrolysis, which specifically cleaves the ribose–ribose bonds between the ADPr subunits of the PAR chains (Fig. 1A) [27,28]. Another enzyme able to reverse protein poly(ADP)ribosylation (PARylation) is ADP-ribosylhydrolase 3 (ARH3) [29]. However, these two enzymes are unable to process MAR attached to a protein [28,29]. Glutamate-linked MAR is known to be removed by macrodomain-containing proteins such as terminal ADPr protein glycohydrolase (TARG1), MacroD1 and MacroD2 [1,30–33] (Fig. 1B). Moreover, human ARH1 has been shown to remove MAR linked to arginine residues [34]. In bacteria, mono-ADP-ribosylation (MARylation) mediated by DraT is reversed by DraG, a protein homologous to human ARH1/ARH3 proteins [5].

Recently, we showed that protein ADP-ribosylation can undergo alternative processing [21,26,35]: rather than complete removal of the ADPr group, the modification can be cleaved down to ribose-5′-phosphate (also known as phosphoribose/pR or R5P), a potentially toxic modification for which it is unclear whether and how it can be removed (Fig. 1C) [36]. This reaction can be supported by phosphodiesterase I from *Crotalus adamanteus* (also referred to as snake venom phosphodiesterase, or SVP) [18,37] as well as the nucleoside diphosphate-linked moiety X (Nudix) family members human NUDT16 [26] and RppH from *Escherichia coli* [35] (Fig. 1A–C).

Here, using PARP1 and PARP10 as *in vitro* models, we have identified a new enzyme, ectonucleotidase pyrophosphatase/phosphodiesterase 1 (ENPP1), belonging to the family of nucleotide pyrophosphatase/phosphodiesterase (NPP) proteins [38], which is able to process protein ADP-ribosylation to generate phosphoribosylated proteins. This enzyme thus implies a new class of proteins in the modulation of mammalian protein ADP-ribosylation and the production of phosphoribosylated protein substrates. Such activity is consistent with the observation of phosphoribosylated proteins in a recent reanalysis of a phosphoproteome dataset [21]. The identification of both acidic and basic protein ADP-ribosylation sites has recently been made possible by the development of a mass spectrometry (MS)-based method [19,37], which relies upon the conversion of protein PAR and MAR into pR by the enzymes SVP [20,37], NUDT16 [26] or RppH [35]. As a new member of this class of enzymes capable of converting protein-conjugated ADP-ribose to pR, we show here that ENPP1 can replace SVP for the identification of PARP1 and PARP10 automodification sites by MS.

**Results**

**NPP-type ectophosphodiesterases**

Phosphoribosylation of cellular proteins has been detected recently [21]. The human Nudix family member NUDT16 has been suggested as an enzyme that
produces this modification by acting on ADP-ribosylated proteins [26,35]. In the search for additional human enzymes able to process protein ADP-ribosylation into pR, we looked for potential human homologues of snake venom phosphodiesterase I from *Crotalus adamanteus* (also known as SVP) [19,20]. SVP belongs to the class of highly conserved nucleotide pyrophosphatase/phosphodiesterase (NPP)-type ectophosphodiesterases/extracellular glycoproteins [38]. These enzymes are known to hydrolyse diesters of phosphoric acid into phosphomonoesters and can be classified, according to the nature of their substrate, into nucleotide and lipid phosphodiesterases [39]. Currently, seven human genes are known to encode NPP protein homologues (ENPP1-7). All human ENPP proteins are unrelated to phospholipases [40], Nudix hydrolases [41] or ectonucleotide triphosphate diphosphohydrolases [42]. Among human NPP enzymes, only ENPP1, ENPP2 and ENPP3 share the same main domains of SVP in addition to the catalytic domain (Fig. 2A,B). Indeed, the mammalian ecto-enzyme NPP2 (autotaxin) has a secretion motif in the N-terminal domain, similar to SVP, while NPP1 (PC-1) and NPP3 (B10; gp130RB13-6) are characterized by a short N-terminal intracellular domain and a single transmembrane domain (Fig. 2B). Except for these differences, all four enzymes share two somatomedin B-like domains, a catalytic domain and a C-terminal nuclease-like domain. C-terminal to the catalytic domain of NPP1–3 is the nuclease-like domain, structurally similar to the DNA- or RNA-nonspecific endonucleases [43]. However, this domain is probably not catalytically active.

---

**Fig. 1.** Metabolism of protein poly- and mono(ADP-ribosyl)ation. Schematic illustration of protein PARylation (A) and MARylation (B). Enzymes and cleavable chemical bonds were indicated in figures. (C) Schematic illustration of protein phosphoribosylation.

---
because none of the residues that are essential for catalysis by the nonspecific endoribonucleases is conserved in NPP1–3. Furthermore, the nuclease-like domain is likely to harbour isoform-specific determinants of catalysis because NPP2 with the nuclease-like domain of NPP1 is inactive [44]. Two somatomedin B-like domains seem required for protein interaction similar to the somatomedin B domain of vitronectin [39]. Members of the ENPP family hydrolyse various phosphodiester bonds (e.g. in oligonucleotides and artificial substrates like the p-nitrophenyl ester of TMP) and pyrophosphate bonds (e.g. in (d)NTP, (d)NDP, NAD, FAD, diadenosine polyphosphates and UDP sugars) and thereby generate nucleoside 5’-monophosphates. In particular, ENPP1 and ENPP3 show specificity to hydrolyse nucleotides [45]. Thus, among the three mammalian ENPP enzymes, ENPP1 and ENPP3 display catalytic properties similar to SVP [46,47]. However, ENPP1 shows much higher hydrolytic activity than ENPP3 in the hydrolysis of various phosphodiester bonds [43]. Activity against ADPr and its use in proteomics of ADP-ribosylated proteins has never been tested for mammalian ENPP proteins [19]. In order to assay activity of mammalian ENPP proteins against protein ADP-ribosylation, we focused on the well-characterized mouse ENPP1 (mENPP1), which has 79% identity with the human ENPP1 protein [48,49]. To purify soluble ENPP1 enzyme, the extracellular and catalytic region of mouse Enpp1 was fused with the secretory signal sequence and the N-terminal nine residues of the somatomedin B-like 1 (SMB1) domain of mouse ENPP2 at the N terminus and, with the addition of a TARGET tag at the C terminus, we generated a recombinant, secreted ENPP2-1 chimera amenable to enrichment via the TARGET tag system (mENPP2-1-T) (top panel Fig. 3A). The protein was then expressed in a clonal human cell line selected for higher activity against p-nitrophenyl ester and purified using a specific antibody capturing the TARGET tag and isolating recombinant protein from cell media [48,49] (left panel Fig. 3B). Of note, mENPP2-1-T was purified from HEK293S GnTI− cells, cells depleted of N-acetyl-glucosaminyltransferase I (GnTI) activity and therefore lack complex N-glycans [48,49]. We also produced an alternative construct for the expression and purification of ENPP2-1 that would enable more accessible and easier purification. For this, we generated and purified an ENPP2-1 chimera with a C terminus eight histidine tag (mENPP2-1-8xHis) from a pool of transiently transfected Exp293™ cells (Bottom panel Fig. 3A, right panel Fig. 3B). Comparison of mENPP2-1-T and mENPP2-1-8xHis protein preparations on SDS/PAGE (left panel Fig. 3C) showed a main band with a molecular weight of ~90 kDa. However, mENPP2-1-8xHis showed an additional high molecular weight contaminant protein. Anti-6xHis western blot confirmed the presence of His-tagged mENPP2-1 protein at ~90 kDa (right panel Fig. 3C). To better investigate the glycosylation pattern in mENPP2-1-T and mENPP2-1-8xHis protein preparations, we performed deglycosylation assays treating both proteins with PNGase F (which removes almost all types of N-linked glycosylation: high mannose, hybrid, bi-, tri- and tetra-antennary) and Endo H (which removes only high mannose and some hybrid types of N-linked carbohydrates) (Fig. 3D). As expected, Coomassie staining revealed that mENPP2-1-T presents a homogeneous glycosylation pattern that can be reverted almost completely by PNGase F treatment (black stars, Fig. 3D). By contrast, mENPP2-1-8xHis showed a complex glycosylation pattern as neither PNGase F nor Endo H was able to completely compact the protein to a single band at a lower molecular weight (Fig. 3D). To test the activity of ENPP1 from both constructs against ADP-ribosylated proteins, we incubated serial dilutions of purified mENPP1 proteins and NUDT16 – a positive control – with automodified PARP1 protein as a substrate for 3 h in the presence of 15 mM MgCl2. PAR was visualized by western blot using an antibody specifically recognizing poly- and oligo-chains of ADPr but not MAR (Fig. 4A–C). Our data showed that ENPP1 successfully removes PAR.

Fig. 2. Alignment and domain analysis of ENPP proteins. (A) Clustal Omega alignment of amino acidic sequences belonging to SVP [gi|818935219|gb|LA1|10403.1] phosphodiesterase [Crotalus adamanteus], human ENPP1 [gi|170650661|ref|NP_006199.2] ectonucleotide pyrophosphatase/phosphodiesterase family member 1 [Homo sapiens], human ENPP2, [gi|91822374|ref|NP_006200.3] ectonucleotide pyrophosphatase/phosphodiesterase family member 2 isofrom 1 preproprotein [Homo sapiens] and human ENPP3 [gi|111160296|ref|NP_005012.2] ectonucleotide pyrophosphatase/phosphodiesterase family member 3 [Homo sapiens]. Legend to the alignment: ‘*’ positions which have a single, fully conserved residue; ‘:’ conservation between groups of strongly similar properties – scoring > 0.5 in the Gonnet PAM 250 matrix; ‘.’: Conservation between groups of weakly similar properties – scoring < 0.5 in the Gonnet PAM 250 matrix. Domains and corresponding residues were highlighted. (B) Representative and schematic illustration of ENPP1, ENPP2, ENPP3 and SVP proteins. Legend of domains: S, signal peptide; TM, transmembrane domain; SO1, somatomedin B-like domain 1; SO2, somatomedin B-like domain 2.
chains from PARP1 protein with activity comparable to that exhibited by NUDT16, though mENPP2-1-T seems to be slightly more active than mENPP2-1-8xHis (Fig. 4A,B). Comparison of mENPP2-1-T and NUDT16 activity showed notably higher activity of NUDT16 against PARylated PARP1 (Fig. 4A,C). All the hydrolases exhibited time-dependent activities (Fig. 4D).
ENPP1 converts protein ADP-ribosylation to protein phosphoribosylation

Hydrolysis assays were again performed, this time using a more sensitive assay in which PARP1 is auto-modified in the presence of NAD$^+$ labelled on the alpha phosphate group with $^{32}$P (Fig. 5A). PARylated PARP1 was then incubated with mENPP2-1-T, PARG (an enzyme known for removing PAR but leaving MAR) or the positive controls SVP and NUDT16 (Fig. 5A,B). As expected, ENPP1 was able to completely remove the radiolabelled PAR signal from PARP1, mirroring the phosphodiester hydrolysis activity of NUDT16 and SVP and failing to leave MAR at the attachment site, as PARG does (Fig. 5A,B). The main product of this reaction was phosphoribosyl AMP (PRAMP) as seen for SVP and NUDT16 previously [19,26,37] (Fig. 5A), [thin layer chromatography (TLC)] (bottom panel Fig. 5B).

In order to directly address whether ENPP1 is able to remove MAR from proteins, recombinant PARP1-E988Q, a PARP1 mutant able to add only a single unit of ADPr onto target proteins (in this case, itself), and a mono-ADP-ribosyl transferase GST-PARP10 catalytic domain, were automodified and then incubated with NUDT16, mENPP2-1-T, PARG or SVP (Fig. 5C). mENPP2-1-T removed the $^{32}$P-labelled MAR signal as efficiently as SVP and NUDT16, thus proving that mENPP2-1-T is active against protein-conjugated MAR. The TLC analysis showed that, as expected, the main reaction product is AMP (Fig. 5D). Taken together, we conclude that ENPP removes PARP-dependent protein ADP-ribosylation.

ENPP1 efficiently removes ARTC2.2-mediated ADP-ribosylation

As mentioned before, ENPP1 is an ecto-enzyme initially described as plasma cell membrane glycoprotein 1 (PC-1, CD203); however, its involvement in lymphocyte biology has not been studied thoroughly [30,38,44,49]. Localization of ENPP1 to the cell surface suggests that ENPP1 may process ADP-ribosylation synthesised by extracellular ADP-ribosyl transferases such as membrane-bound cholera-like ecto-ADP-ribosyltransferases (ARTCs) [7–9]. Unlike PARPs, these enzymes usually modify protein arginine residues [6,7]. In particular, we focused on the ARTC2.2 protein expressed as an ecto-enzyme on the plasma membrane of mouse immune cells [50]. ARTC2.2 is known to have a crucial regulatory function on the activity and survival of T lymphocytes and NK lymphocytes, ADP-ribosylating several proteins, such as the purinergic P2X7 receptor, LFA-1 and CD8 [50]. To address the question of whether ENPP1 can remove ARTC2.2-dependent ADP-ribosylation in a cellular context, we expressed and purified the catalytic domain of mouse ARTC2.2 (mARTC2.2) in and from E. coli and then in vitro incubated the ART recombinant protein with K562 (human NK lymphocyte) cell extract in the presence of radiolabelled NAD$^+$ (Fig. 6A). Under these conditions, mARTC2.2 was able to reproducibly modify several proteins in the K562 cell extract. Concomitant incubation of mARTC2.2 modified extract with NUDT16 showed significant reduction in radiolabelled ADP-ribosylated proteins; however, incubation of cellular proteins with the same concentrations of mENPP2-1-T gave rise to an even more remarkable hydrolysis of mono-ADP-ribosylated proteins. Of note, NUDT16 was itself modified by mARTC2.2. Our data show that ENPP1 can better perform conversion of ADP-ribosylated proteins into pR-proteins than NUDT16 in this cell-free system and reaction conditions. Taken together, our data demonstrate that ENPP1 is able to remove ARTC-mediated ADP-ribosylation in vitro, and suggest that this event may occur in vivo due to the extracellular proximity of ARTCs and ENPPs.

ENPP1 as a tool for LC-MS/MS aided identification of protein ADP-ribosylation sites

In order to determine whether ENPP2-1 can serve as a replacement for SVP in the recently established ADPr site identification proteomics pipeline [19,35], we treated 60 pmoles of autoPARylated PARP1 protein with 120 pmoles of SVP, mENPP2-1-T or mENPP2-1-8xHis, or 600 pmoles of mENPP2-1-T or mENPP2-1-
ENPP1 processes protein ADP-ribosylation in vitro

**A**

| mENPP2-TARGET | mENPP2 | mENPP1 |
|---------------|--------|--------|
| N             | SO     | SO     |
| Catalytic domain |       | Nuclease-like domain |
| TARGET tag    |        | C      |

| mENPP2-1-8xHis | mENPP2 | mENPP1 |
|---------------|--------|--------|
| N             | SO     | SO     |
| Catalytic domain |       | Nuclease-like domain |
| 8xHis         |        | C      |

**B**

1. HEK293
2. HEK293
3. mENPP2-1-T
4. Transfection
5. G418
6. Isolation of single colonies by serial dilutions
7. Screening of colonies: pNIP-TMP assay in culture supernatants
8. Expansion of selected stable cells for three weeks
9. Clarification of the culture supernatant by centrifugation
10. P20.1 antibody-agarose resin
11. PRGYPQDV
12. Peptide-mediated elution
13. S2000 Gel-filtration
14. Ni-NTA
15. Imidazole-mediated elution
16. 5200 Gel-filtration

**C**

| mENPP2-1-T | mENPP2-1-8xHis | kDa |
|------------|---------------|-----|
| Coomassie  | α-6xHis       |     |
| 191        | 97            | 64  |
| 51         | 39            | 28  |
| 19         | 14            |     |

**D**

**Deglycosylation assay**

| mENPP2-1-T | mENPP2-1-8xHis | CTR | PNGase F | Endo H | kDa |
|------------|---------------|-----|----------|--------|-----|
|            |               |     | –        | –      | 191 |
|            |               |     | –        | –      | 97  |
|            |               |     | –        | –      | 64  |
|            |               |     | –        | –      | 51  |
|            |               |     | –        | –      | 39  |
|            |               |     | –        | –      | 28  |
|            |               |     | –        | –      | 19  |
|            |               |     | –        | –      | 14  |

* ENPP2-1 glycosylated

* ENPP2-1 de-glycosylated

* ENPP2-1 de-glycosylation resistant
Fig. 4. ENPP1 is able to hydrolyse protein poly(ADP-ribosylation). About 70 nM of human recombinant PARP1 was automodified to produce ~3 μM PAR substrate (defined in monomeric ADP-ribose units) and incubated with buffer only (control) and decreasing concentrations of mENPP2-1-T (A), mENPP2-1-8xHis (B) and NUDT16 (C). Samples were fractionated on SDS/PAGE and transferred on nitrocellulose membranes. Membranes were first stained with S-Ponceau and then probed with anti-PAR antibody. (D) Time point hydrolysis of PARYlated PARP1 was performed at indicated concentrations and times with NUDT16, mENPP2-1-T and SVP. Samples were resolved on SDS/PAGE and transferred on nitrocellulose membranes. Membranes were first stained with S-Ponceau and then probed with anti-PAR antibody.
8xHis and used LC-MS/MS to search for the 212.01 Da shift characteristic of pR-modified peptides. Ten PARP1 peptides confidently presented with an MS1 mass shift corresponding to a singly or doubly phosphoribosylated state combined with peptide sequencing by MS2 to determine site localization (Table 1). As shown in Fig. 7, panels A and B, the ambiguity in site localization as reported by Max-Quant can often be overcome by de novo sequencing of the spectrum of interest, shown here for the first two forms of peptide 3, where pR is carried on E168 (panel A) and E169 (panel B). A direct comparison between the peptide forms identified following SVP, mENPP-2-1-T or mENPP-2-1-8xHis digestion is depicted in the ‘2x’ columns of Table 1, wherein the enzymes were incubated with PARylated PARP1 in a 2 : 1 molar ratio (note that this ratio is for enzyme: protein, not enzyme:substrate, where the substrate would be ADPr). Of the 19 peptide forms identified in this analysis, 15 were found following exposure to SVP, 16 following mENPP-2-1-T and 11 following mENPP-2-1-8xHis, demonstrating the comparability of these three enzymes in this application. To determine whether these reactions can be driven to completion by the addition of excess enzyme, the ENPP1 proteins were added in a 10 : 1 enzyme/PARylated protein ratio (see Table 1, columns labelled 10x), resulting in 19/19 peptide forms being identified in the mENPP-2-1-T sample and 9/19 peptide forms showing up in the mENPP-2-1-8xHis sample. This result suggests that, at least in the case of the highly active form of ENPP1 (mENPP-2-1-T), the transformation of PAR to pR can be driven to completion by the addition of more recombinant enzyme.

In order to confirm that ENPP1 is able to convert protein-conjugated mono(ADP-ribose) to a pR tag, we automodified the catalytic domain of PARP10 – an enzyme restricted to mono(ADP-ribosylation activity – and exposed it to mENPP-2-1-T. This resulted in the confident identification of four pR-containing PARP10 peptides after ENPP1 treatment (Table 2). K916, a residue previously identified as a PARP10 automodification site [18] and also known to be acetylated [51], was among the identified mono(ADP-riboseylated sites.

**Discussion**

ENPP1 is a type II transmembrane glycoprotein with nucleotide phosphodiesterase activity [38,39]. This protein has broad specificity and cleaves a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars, and pyrophosphate bonds of nucleotides and nucleotide sugars. This protein may function to hydrolyse nucleoside 5’ triphosphates to their corresponding monophosphates and may also hydrolyse diadenosine polyphosphates [38,39,46,47].

Mutations in the ENPP1 gene have been associated with ‘idiopathic’ infantile arterial calcification [52], ossification of the posterior longitudinal ligament of the spine OPLL [53], hearing loss [54] and insulin resistance [49]. ENPP1 has been described as essential for physiological mineralization because its expression on the outer surfaces of mineralizing cells, such as osteoblasts and chondrocytes, regulates the balance between the extracellular concentrations of inorganic phosphate (Pi), a substrate for mineralization, and inorganic pyrophosphate (PPi), an inhibitor of mineralization [55]. Although ENPP1 is essential for the regulation of physiological mineralization, its substrate specificity for different nucleotides is not completely described.

While aligning the nucleotide sequences of the ectonucleotide pyrophosphatase/phosphodiesterase enzymes with SVP, we hypothesized that ENPP1 could act in a similar manner as SVP to convert ADP-ribosylated proteins into proteins containing a pR tag. In addition to the wide range of intracellular roles played by PAR, its recently observed presence in the extracellular matrix (ECM) suggests an extracellular function for this polymer [56]. In particular, PAR was identified in the ECM of developing bones, where it was likely released from necrotic osteoblasts and playing an essential role as a scaffold for bio-mineralization [56].

Our biochemical data suggest that ENPP1 may be involved in the metabolism of extracellular PAR through its hydrolysis and release of phosphoribosylated proteins, PRAMP and, contextually, free PAR – a molecule that has previously been described as an extracellular stimulus driving inflammatory signalling [57]. Moreover, colocalization of ARTCs and ENPP1 on the extracellular membrane [50] may suggest a physiological function for ENPP1 in the regulation of immune cell activity and survival.

The advent of mass spectrometry-based methods for identifying ADP-ribosylation sites has allowed for large-scale assessments of the endogenously ADP-ribosylated proteome at the protein sequence level in human and murine cells [19,58]. All of the available methods for PAR site identification rely upon the creation of a molecular ‘tag’ at the PTM’s amino acid attachment site [20], in the case of SVP digestion this tag is pR. SVP, however, must be purified from snake venom through a multi-step process, resulting in a high prep-to-prep variation due to both source variability (at the level of the snake venom) and inevitable...
ENPP1 processes protein ADP-ribosylation in vitro

L. Palazzo et al.

---

**Figure A**

![Diagram showing the process of ADP-ribosylation](image)

**Figure B**

| Condition       | Autoradiography |
|-----------------|-----------------|
| Buffer          | PARP1           |
| Buffer + NUDT16| PARP-E988Q      |
| Buffer + mENPP2-1-T | PARP10cd     |

**Figure C**

| Condition       | Autoradiography |
|-----------------|-----------------|
| Buffer          | PARP-E988Q      |
| Buffer + NUDT16| PARP10cd       |
| Buffer + mENPP2-1-T | PARP10cd     |

**Figure D**

| Condition       | Autoradiography |
|-----------------|-----------------|
| Buffer          | PARP-E988Q      |
| Buffer + NUDT16 | PARP10cd       |
| Buffer + mENPP2-1-T | PARP10cd     |

---

The FEBS Journal 283 (2016) 3371–3388 © 2016 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
inconsistencies between protein purification pipelines (at the level of instrumentation, reagents, etc.) [26,35]. Therefore, in order to broadly implement the pR pipeline for proteomics applications, it is necessary to replace SVP with a phosphodiesterase that can be made in large quantities and with high consistency (as a recombinant protein, expressed and purified in the laboratory). We have presented two options for this purpose: mENPP2-1-T and mENPP2-1-8xHis. Of these two, the former (mENPP2-1-T) has proven to be

**Fig. 5.** ENPP1 is able to hydrolyse protein poly- and mono-(ADP-ribosyl)ation producing PRAMP and AMP. (A) Schematic illustration of protein ADP-ribosylation in the presence of NAD\(^+\) labelled on the alpha phosphate group with \(^{32}\)P. Enzymes used in experiments showed in panels B–D, and cleavable chemical bonds in radiolabelled MAR/PAR were indicated. Main reaction products of phosphodiesterases-dependent hydrolysis of radiolabelled protein PARylation were represented. (B) Human recombinant PARP1 was automodified in the presence of \(^{32}\)P-NAD\(^+\) and then incubated with buffer (Control), 18 \(\mu\)M of recombinant NUDT16, 4 \(\mu\)M of recombinant ENPP2-1-T, 1 \(\mu\)M of PARG and 0.45 \(\mu\)M of purified SVP for 3 h at 30 °C. In top panel, samples were resolved on SDS/PAGE and \(^{32}\)P-NAD\(^+\) incorporation was detected by autoradiography. In bottom panel, reactions described in top panel were loaded on TLC plate. (C) Top panel, 1 \(\mu\)M of recombinant PARP1-E988Q mutant was automodified using \(^{32}\)P-labelled NAD\(^+\) and then incubated with buffer only (control), 5 \(\mu\)M of recombinant NUDT16, 5 \(\mu\)M of recombinant mENPP2-1-T or 2 \(\mu\)M of purified SVP. Samples were resolved on SDS/PAGE and \(^{32}\)P-NAD\(^+\) incorporation was detected by autoradiography. Bottom panel, 1 \(\mu\)M of recombinant GST-PARP10cd was automodified and treated as indicated in top panel. (D) The products of indicated enzymatic reactions were assayed by TLC.

**Fig. 6.** ENPP1 efficiently in vitro neutralize ARTC2.2-dependent ADP-ribosylation of cellular proteins. (A) K562 cell extract was supplemented with 37 kBq of \(^{32}\)P-labelled NAD\(^+\) and 15 mM MgCl\(_2\). Then, the extract was incubated with or without 1 \(\mu\)M of recombinant mARTC2.2 for 15 min. Subsequently, the extract was incubated with or without NUDT16 or mENPP2-1-T at the indicated concentrations. Top panel, samples were resolved on SDS/PAGE and \(^{32}\)P-NAD\(^+\) incorporation was detected by autoradiography. Bottom panel, Coomassie staining of dried gel exposed in top panel.
ENPP1 processes protein ADP-ribosylation in vitro

L. Palazzo et al.

Table 1. ENPP1 as a tool for LC-MS/MS aided identification of protein ADP-ribosylation sites. PARP1 automodification sites identified using the pipeline described by Daniels et al. [19]. Experimental conditions were described in the main text. Posterior error probabilities (PEPs) are reported for corresponding amino acid residues as well as site localization probabilities within the identified pR-containing peptides. The 2× and 10× columns refer to the reaction ratio of enzyme to PARylated PARP1. Key at the bottom describes the confidence ranges reported by MaxQuant for site identification (with possible modification sites of D, E, K and R); often this ambiguity can be resolved by manual inspection of the peptide fragmentation pattern [see Fig. 7 for annotation of two different forms of peptide N166-K182].

| No. of pR | Mass error (ppm) | Posterior error probability | Intensity |
|-----------|------------------|-----------------------------|-----------|
| 66-HPDVEVDGFS*LR | -78 | 1 | 2.0 | 3.8E–48 | 7.6E+05 | 5.6E+05 | 2.6E+06 | 7.6E+05 |
| 143-MVP*PEKPOLGMIDR | -156 | 1 | -0.15 | 1.8E–25 | 7.6E+05 | 2.6E+06 | 4.6E+06 | 5.6E+05 | 2.6E+05 |
| 166-NREELGRFPEYSASQLK | -182 | 1 | 0.99 | 2.4E–11 | 5.6E+05 | 4.6E+06 | 3.6E+05 | 1.6E+06 |
| 183-GFSSLATE*DK | -192 | 1 | 0.12 | 9.2E–33 | 1.6E+05 | 2.6E+05 | 1.6E+06 | 2.6E+05 |
| 338-EFPLFSYILK | -346 | 1 | 1.71 | 2.2E–02 | 2.6E+05 | 4.6E+05 | 7.6E+05 |
| 468-SLQ*E*LFLAHILSPWGAEVK | -486 | 1 | -0.45 | 3.4E–04 | 5.6E+05 | 1.6E+06 | 3.6E+06 | 6.6E+05 | 2.6E+06 |
| 487-AP*PVUEVAPR | -496 | 1 | -0.13 | 5.2E–23 | 6.6E+06 | 8.6E+06 | 3.6E+07 | 2.6E+06 | 1.6E+06 |
| 630-NFT*KYPK | -637 | 1 | 2.82 | 2.1E–02 | 5.6E+05 | 5.6E+06 | 4.6E+06 |
| 638-EFPLEIDVGQDEAVK | -653 | 1 | 3.48 | 2.6E–27 | 1.6E+06 | 1.6E+06 | 4.6E+06 | 1.6E+06 | 1.6E+06 |
| 788-DPIVNYE*K | -796 | 2 | 1.57 | 7.6E–04 | 2.6E+05 | 2.6E+05 | 9.6E+05 |

pR probabilities: 100% = E* 75 – 99% = E 25 – 74% = E 1 – 24% = E 0% = E

Fig. 7. ENPP1 hydrolyses poly(ADP-ribose) to pR, a molecular tag detectable by LC-MS/MS. (A) PARP1 carries a 212.01 Da shift representative of pR on E168. (B) PARP1 carries pR on E169, as shown here clearly distinguishable from the pR-E168 peptide form. Both peptides detected following digestion of PAR by ENPP2-1-T in a 10× enzyme:PARP ratio.

a more active form of this enzyme, while the latter (NENPP2-1-8xHis) can more easily be adapted for expression and purification in standard laboratories equipped to purify His-tagged proteins. The availability of these tools will allow for greater adoption and implementation of the pR-based proteomics pipeline for the unbiased identification of protein mono and poly(ADP-ribosylation)ation sites.
Materials and methods

Plasmids and recombinant proteins

PARP1 wild-type protein was purchased from Trevigen Inc., (Gaithersburg, MD, USA) (high specific activity) for biochemical assays or expressed and purified as previously described [19] for analysis by mass spectrometry. PARP1-E988Q was expressed from pET28a(+) and purified as previously described [30]. NUDT16 was expressed from pNIC28-Bsa4 and purified as described in Palazzo et al. [26]. pGEX-4T1 GST-PARP10cd (amino acids 818–1025) plasmid was a gift from Bernhard Lüscher (RWTH Aachen University) [17]. GST-PARP10cd recombinant protein was purified from transformed Rosetta2 (DE) competent cells. Briefly, transformed bacteria were grown over night in LB supplemented with 100 μg/mL of ampicillin and 34 μg/mL chloramphenicol at 37 °C. Overnight culture was diluted in 4 L of media and grown at 37 °C until the absorbance measured at 600 nm reached 0.8. Temperature was then cooled down to 18 °C, bacteria were induced with 0.2 mM IPTG and culture was prolonged for 16 h. Bacteria were then lysed using BugBuster protein extraction reagent [Novagen (Merck Biosciences), Beeston, Nottingham, UK] and the following primers containing the extensions necessary for ligation-independent cloning (Forward primer: aggagatatacatgATGGCAAGACAAAGCCTGGTTCGG and reverse primer:gtgatggtgatgtttGTCTTCTTGGCTGAAGAT TGGCAAATGT). The PCR product was cloned into pOPI-

Table 2. ENPP1 as a tool for LC-MS/MS aided identification of protein mono-ADP-ribosylation sites in PARP10 catalytic domain. Posterior error probabilities (PEPs) are reported for corresponding amino acid residues as well as site localization probabilities within the identified pR-containing peptides. Two replicates for mENPP-2-1-T treated samples are shown. Key at the bottom describes the confidence ranges reported by MaxQuant for site identification.

| Peptide pR probabilities | No. of pR | Mass error (ppm) | Posterior error probability | Intensity |
|--------------------------|-----------|------------------|-----------------------------|-----------|
|                          |           |                  |                             | ENPP-2-1-Target |
|                          |           |                  |                             | Rep 1     |
|                          |           |                  |                             | Rep 2     |
| 836- AFYD*TLDAA*         | -845      | 1                | 0.31                        | 7.9E–04   |
|                          |           |                  |                             | 4.E+06    |
|                          |           |                  |                             | 6.E+06    |
| 910- NATVYGR*GYYFAR      | -922      | 1                | -0.99                       | 3.3E–04   |
|                          |           |                  |                             | 9.E+05    |
|                          |           |                  |                             | 9.E+05    |
| 924- ASLSVOQDRSPNNADHE   | -941      | 1                | 0.15                        | 2.4E–03   |
|                          |           |                  |                             | 1.E+06    |
| 948- VLTGD*YGQGR          | -957      | 1                | 0.10                        | 1.6E–02   |
|                          |           |                  |                             | 7.E+05    |
|                          |           |                  |                             | 5.E+05    |
| 1010- ASPDDPGLPGSPDT      | -1025     | 1                | -0.88                       | 2.2E–11   |
| ASPDPDSLPGSPRDT          |           | 1                | -1.81                       | 1.5E–139  |
| ASPDDPDSLPGSPRT          |           | 1                | 0.42                        | 9.9E–05   |

pR probabilities: 100% = E; 75 – 99% = E; 25 – 74% = E; 1 – 24% = E; 0% = E

ENPP1 processes protein ADP-ribosylation in vitro

L. Palazzo et al.
enlarged using 1 M KPO₄ buffer. Desired fractions were 500 mM NaCl, 500 mM imidazole and the eluted sample was pure (GE Healthcare) in a buffer composed of 10 mM Tris pH 8.0, 50 mM NaCl, 15 mM MgCl₂ and 1% glycerol. Concentration of desired fractions (and 1.5 mL of ExpiFectamine Transfection [62]) were added to the transfected cells. The supernatant containing the mENPP2-1-8xHis protein was harvested after 96 h. Secreted protein was purified by automated immobilized metal affinity chromatography followed by gel filtration chromatography using the method of Nettleship et al. [60,61]. Briefly, 200 mL of sample was loaded onto a 5 mL HisTrap FF column (GE Healthcare) before washing with 50 mL of 50 mM Tris pH 7.5, 500 mM NaCl, 30 mM imidazole. This was then repeated until all the samples were loaded. Elution from the HisTrap FF column was of 50 mM Tris pH 7.5, 500 mM NaCl, 500 mM imidazole and the eluted sample was injected directly onto a HiLoad 16/600 Superdex 200 column. Size exclusion chromatography was performed using 20 mM Tris pH 7.5, 200 mM NaCl and the fractions analysed by SDS/PAGE. The fractions containing the ENPP1 protein were concentrated to 2.1 mg·mL⁻¹, based on an extinction coefficient of 1 Au = 1 mg·mL⁻¹ (0.63 mg final yield) before use. pASK60-OmpA-mARTC2.2 6xHis-Flag tag was a gift from Friedrich Koch-Nolte (Universitätsklinikum Hamburg-Eppendorf) and purified as previously described [62].

**Purification of snake venom phosphodiesterase**

Phosphodiesterase I (SVP) from *Crotalus adamanteus* venom was purified as previously described [19,26]. Briefly, ~ 2.52 mg dried weight of partially purified SVP (Worthington Biochemical Corporation, Lakewood, NJ, USA) was dissolved in 1 mL of loading buffer (10 mM Tris/HCl pH 7.5, 50 mM NaCl, 10% glycerol) and loaded onto a pre-equilibrated 1 mL HiTrap blue HP (GE Healthcare). The column was washed with five column volumes (CV) of loading buffer followed by an increasing gradient of KPO₄ pH 8.0 up to 150 mM. The SVP protein was eluted using 1 mM KPO₄ buffer. Desired fractions were pooled and loaded onto analytical size-exclusion chromatography Superdex 200 (GE Healthcare) using ÄKTA pure (GE Healthcare) in a buffer composed of 10 mM Tris pH 8.0, 50 mM NaCl, 15 mM MgCl₂ and 1% glycerol. Concentration of desired fractions (~ 97 kDa molecular weight) was measured using Nanodrop (Thermo Fisher Scientific) and stored at −80 °C.

**Hydrolytic activity assays on ADP-ribosylated proteins**

PARylated and MARylated PARP1 proteins were prepared as described [26] in a reaction buffer containing 50 mM Tris/HCl (pH 8.0), 4 mM MgCl₂, 50 mM NaCl, 0.2 mM DTT, 200 μM NAD+ (Trevigen) and 130 ng activated DNA (BPS Bioscience, Inc., San Diego, CA, USA). Briefly, for the PAR hydrolysis activity assays, 70 nM PARP1 (PARP1-HSA; Trevigen) was automodified as described in [26]. After 20-min incubation, PARP1 was passed three times through SpinTrap G-25 (GE Healthcare). PARylated PARP1 substrate was used in a 10-μL reaction. For the MARylated PARP1, 1 μM of PARP1-E988Q was used as a substrate. Reactions were stopped by the addition of PARP inhibitor Olaparib (1 μM). The MgCl₂ (Sigma) concentration was adjusted to 15 mM to allow full hydrolase activity. Automodified PARP1 was then incubated for indicated times at 30 °C with hydrolytic enzymes in 10-μL reaction. Concentrations of hydrolytic enzymes used are as indicated in figures. Reactions were stopped by addition of Laemmli loading buffer, samples boiled at 90 °C for 1.5 min and analysed by NuPAGE Novex Bis-Tris 4–12% gel using MOPS buffer (Invitrogen). Radiolabelled experiments were visualized by autoradiography.

**Thin layer chromatography**

The TLC was performed as previously described [26]. PARylated PARP1 and MARylated PARP1-E988Q/GST-PARP10cd proteins were automodified in the presence of [³²P]-labelled NAD⁺ as described above. The product of this reaction was then cleaned up by G25 desalting columns, MgCl₂ was added to a final concentration of 15 mM and 10-μL reaction samples were processed by NUDT16, ENPP1, PARG and SVP, as described above. About 1 μL of reaction was spotted onto polyethylenimine (PEI)-cellulose plates (Macherey-Nagel, Polygram CEL 300 PEI/UV254) and developed in 0.15 M LiCl and 0.15 M formic acid. Dried plates were exposed on X-ray film or visualized by UV254 shadowing.

**Immunoblotting**

Fractionated proteins on gradient gels were transferred onto nitrocellulose membranes using Trans-Blot Turbo Transfer System (Biorad) at 1.3 A/25 V for 20 min. Membranes were blocked in 5% nonfat dry milk (NDFM; Bio-Rad Laboratories Ltd., Hemel Hempstead, UK) diluted in 0.1% Tween 20-PBS and subsequently incubated with rabbit polyclonal anti-PAR (1 : 2000; Trevigen) and mouse monoclonal anti-6xHis (1 : 4000; Clontech). Primary antibody incubation was then followed by incubation with secondary antibody as indicated and developed with ECL western blotting detection reagent (GE Healthcare).

**Deglycosylation assay**

PNGase F and Endo H enzymes were purchased from New England BioLabs and reactions were performed according to the manufacturer’s protocols under denaturant conditions using 1 μg of recombinant substrate.
**In vitro cell extract modification**

K562 NK cell lines (ATCC) were cultured in RPMI-1640 (+L-Glutamine) supplemented with 10% inactivated foetal bovine serum (Life Technology, Thermo Fisher Scientific) and 1% penicillin/streptomycin. About 8 x 10⁶ cells were washed twice in PBS and then lysed 20 min in 50 mM Tris/HCl pH 7.5, 150 mM NaCl. The 6xHis-hsPARP1 was denatured in 8M urea, washed twice in PBS and then lysed 20 min in 50 mM Tris pH 7.0 for 10 min at 37°C. After centrifugation at 15 900 g for 15 min at 37°C, the supernatant was applied to a 5 mL HisTrap Crude FF column (GE), washed with 10 column volumes of binding buffer and eluted with binding buffer supplemented with imidazole to 250 mM. The eluent was desalted into binding buffer and incubated with 6xHis-SENp SUMO protease for 2 h at 4°C at a 1 : 50 enzyme:substrate ratio. Untagged PARP-10818 was then purified further by reverse IMAC on a 1 mL HisTrap Crude FF column (GE) and gel filtration chromatography on a Superose 12 10/300 column (GE) into storage buffer (20 mM Tris pH 7.0, 200 mM NaCl, 5% glycerol and 1 mM DTT). Aliquots were snap frozen in liquid nitrogen and stored at −80°C. For each reaction, 20 μg of PARP-10818 was incubated with 1 mM NAD⁺ in automodification buffer (20 mM Tris pH 7.5, 50 mM NaCl, 5 mM MgCl2 and 20 mM BME) at 30°C for 30 min to induce mono(ADP-ribosyl)ation. The reaction was then supplemented with MgCl₂ to a 15 mM concentration and 2 μg of ENPP-2-1-T was then added to the reaction and incubated at 37°C for 120 min. The 2× denaturing buffer (200 mM Tris pH 7.5, 3 M guanidine hydrochloride, 2 mM CaCl₂, 10 mM TCEP and 20 mM CAM) was added to a 1× concentration and incubated at 95°C in the dark for 10 min. Trypsin and LysC were added at a 1 : 20 enzyme:substrate ratio and incubated at 37°C overnight. Phosphoribosylated and phosphorylated peptides were then enriched and desalted on in-house C18 StageTips overlaid with PHOS-Select IMAC resin (Sigma) and analysed by LC-MS/MS as previously described [19]. Raw data were analysed as previously described [19].

**Preparation of pR-tagged PARP1 for analysis by LC-MS/MS**

The 6xHis-hsPARP1 (wild-type) was expressed and purified from E. coli, attached to MagneHis beads (Promega Corporation, Madison, WI, USA), and PARylated as described previously [19] with the following changes: PARP1 (final concentration 1 μM) was autoPARylated in the presence of 1 mM β-NAD⁺ for 30 min at 37°C. After about 60 μmol of PARP1, 6xHis-hsPARP1 was then exposed to 120 μmol of SVP, 120 μmol of ENPPs or 600 μmol of ENPPs for 2 h at 37°C in the presence of 50 mM Tris pH 7.5, 150 mM NaCl, 15 mM MgCl2 and 1 mM 3-aminobenzamide. The 6xHis-hsPARP1 was denatured in 8 μM urea, 50 mM Tris pH 7.0 for 10 min at 37°C and then reduced in 1 μM TCEP (Tris-(2-carboxyethyl)phosphine) for 10 min at 37°C and alkylated in 2 mM CAM (2-chloroacetamide) for 10 min at 37°C in the dark. Samples were diluted to final concentrations: 1 μM urea, 0.2 μM Tris/HisCl pH 7.0, 50 mM NaCl, 15 mM MgCl₂ and 1 mM CaCl₂. Trypsin (Promega) and LysC (Wako, Richmond, VA, USA) were added at a 1 : 50 enzyme:substrate ratio and digestion was carried out overnight (16-18 h).

**Preparation of pR-tagged PARP-10 for analysis by LC-MS/MS**

The catalytic domain of human PARP-10 (residues 818–1025) was cloned from pEGFP-PARP-10 into a pBAT4-derived vector with an N-terminal 6xHis-SUMO tag. The construct was transformed and expressed in DE3 Rosetta E. coli cells that were cultured to an OD of 0.5 at 37°C, induced with 0.3 mM IPTG and grown overnight at 16°C. The cells were harvested the next morning, lysed by sonication in binding buffer (25 mM HEPES pH 7.0, 500 mM NaCl, 20 mM imidazole pH 7.4, 10% glycerol, 20 mM beta-mercaptoethanol (BME) and SigmaFast Protease Inhibitor (Sigma) at a 1 x concentration) and cleared by centrifugation. The supernatant was applied to a 5 mL HisTrap Crude FF column (GE), washed with 10 column volumes of binding buffer and eluted with binding buffer supplemented with imidazole to 250 mM. The eluent was desalted into binding buffer and incubated with 6xHis-SENp SUMO protease for 2 h at 4°C at a 1 : 50 enzyme:substrate ratio. Untagged PARP-10818 was then purified further by reverse IMAC on a 1 mL HisTrap Crude FF column (GE) and gel filtration chromatography on a Superose 12 10/300 column (GE) into storage buffer (20 mM Tris pH 7.0, 200 mM NaCl, 5% glycerol and 1 mM DTT). Aliquots were snap frozen in liquid nitrogen and stored at −80°C. For each reaction, 20 μg of PARP-10818 was incubated with 1 mM NAD⁺ in automodification buffer (20 mM Tris pH 7.5, 50 mM NaCl, 5 mM MgCl₂ and 20 mM BME) at 30°C for 30 min to induce mono(ADP-ribosyl)ation. The reaction was then supplemented with MgCl₂ to a 15 mM concentration and 2 μg of ENPP-2-1-T was then added to the reaction and incubated at 37°C for 120 min. The 2× denaturing buffer (200 mM Tris pH 7.5, 3 M guanidine hydrochloride, 2 mM CaCl₂, 10 mM TCEP and 20 mM CAM) was added to a 1× concentration and incubated at 95°C in the dark for 10 min. Trypsin and LysC were added at a 1 : 20 enzyme:substrate ratio and incubated at 37°C overnight. Phosphoribosylated and phosphorylated peptides were then enriched and desalted on in-house C18 StageTips overlaid with PHOS-Select IMAC resin (Sigma) and analysed by LC-MS/MS as previously described [19]. Raw data were analysed as previously described [19].

**Acknowledgements**

The authors thank Bernhard Lüscher and Friedrich Koch-Nolte for sharing pGEX-4T1 GST-PARP10cd, pEGFP-PARP10 and pASK60-OmpA-mARTC2.2 6xHis-Flag-tag respectively. The authors also thank Benjamin Thomas (Central Proteomic Facility, Sir William Dunn School of Pathology) and members of IA and AKLL laboratories for their helpful suggestions. The work in IA laboratory was supported by the Wellcome Trust (grant number 101794) and the European Research Council (grant number 281739). LP was supported by an Italian Cancer Research Foundation (FIRC) fellowship for abroad and currently supported by Wellcome Trust. The work in AKLL laboratory was funded by an NIH grant R01-
GM104135, American Cancer Society Research Scholar Award 129539-RSG-16-062-01-RMC, the Safeway Research Foundation, the Patrick C. Walsh Prostate Cancer Research Fund, the Allegheny Health Network–Johns Hopkins Cancer Research Fund and the Johns Hopkins Catalyst Award. CMD was supported by an NCI training grant 5T32CA009110. RLM was supported by R01-GM104135S1. SEO was supported by an NIAMS grant R01AR065459. The OPPF-UK was funded by the Medical Research Council (grant no. MR/K018779/1).

Conflicts of interest
The authors declare no competing financial interests.

Author contributions
LP made the initial observation; LP, IA, CMD and AKLL conceived and planned the experiments; LP, CMD, RLM and SEO performed MS/MS experiments; LP, IA, CMD and AKLL wrote the manuscript; LP, CMD, RLM, JEN, NR, KK and ON cloned and purified proteins; all authors read and approved the final version of this manuscript.

References
1 Barkauskaite E, Jankevicius G & Ahel I (2015) Structures and mechanisms of enzymes employed in the synthesis and degradation of PARP-dependent protein ADP-ribosylation. Mol Cell 58, 935–946.
2 Grimaldi G, Corda D & Catara G (2015) From toxins to mammalian enzymes: the diversity of mono-ADP-ribosylation. Front Biosci (Landmark Ed) 20, 389–404.
3 Perina D, Mikoč A, Ahel J, Cetković H, Zaja R & Ahel I (2014) Distribution of protein poly(ADP-ribosyl)ation systems across all domains of life. DNA Repair 23, 4–16.
4 Gibson BA & Kraus WL (2012) New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 13, 411–424.
5 Moure VR, Costa FF, Cruz LM, Pedrosa FO, Souza EM, Li XD, Winkler F & Huergo LF (2015) Regulation of nitrogenase by reversible mono-ADP-ribosylation. Curr Top Microbiol Immunol 384, 89–106.
6 Hottiger MO, Hassa PO, Luscher B, Schuler H & Koch-Nolte F (2010) Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem Sci 35, 208–219.
7 Laing S, Unger M, Koch-Nolte F & Haag F (2011) ADP-ribosylation of arginine. Amino Acids 41, 257–269.
8 Koch-Nolte F, Kernstock S, Mueller-Dieckmann C, Weiss MS & Haag F (2008) Mammalian ADPribosyltransferases and ADP-ribosylhydrolases. Front Biosci 13, 6716–6729.
9 Corda D & Di Girolamo M (2003) Functional aspects of protein mono-ADP-ribosylation. EMBO J 22, 1953–1958.
10 Flick F & Luscher B (2012) Regulation of sirtuin function by posttranslational modifications. Front Pharmacol 3, 29.
11 Rack JG, Morra R, Barkauskaite E, Kraehenbuehl R, Ariza A, Qu Y, Ortmayer M, Leidecker O, Cameron DR, Matic I et al. (2015) Identification of a class of protein ADP-ribosylating sirtuins in microbial pathogens. Mol Cell 59, 309–320.
12 Jwa M & Chang P (2012) PARP16 is a tail-anchored endoplasmic reticulum protein required for the PERK- and IRE1α-mediated unfolded protein response. Nat Cell Biol 14, 1223–1230.
13 Chang P, Coughlin M & Mitchison TJ (2005) Tankyrase-1 polymerization of poly(ADP-ribose) is required for spindle structure and function. Nat Cell Biol 7, 1133–1139.
14 Palazzo L, Della Monica R, Visconti R, Costanzo V & Greico D (2014) ATM controls proper mitotic spindle structure. Cell Cycle 13, 1091–1100.
15 Langelier MF & Pascal JM (2013) PARP-1 mechanisms for coupling DNA damage detection to poly(ADP-ribose) synthesis. Curr Opin Struct Biol 23, 134–143.
16 Leung AK, Vyas S, Rood JE, Bhtukar A, Sharp PA & Chang P (2011) Poly(ADP-ribose) regulates stress responses and microRNA activity in the cytoplasm. Mol Cell 42, 489–499.
17 Kleine H, Poreba E, Lesniewicz K, Hassa PO, Hottiger MO, Litchfield DW, Shilton BH & Lüscher B (2008) Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation. Mol Cell 32, 57–69.
18 Vyas S, Matic I, Uchima L, Rood J, Zaja R, Hay RT, Ahel I & Chang P (2014) Family-wide analysis of poly(ADP-ribose) polymerase activity. Nat Commun 5, 4426.
19 Daniels CM, Ong SE & Leung AK (2014) Phosphoproteomic approach to characterize protein mono- and poly(ADP-ribosyl)ation sites from cells. J Proteome Res 13, 3510–3522.
20 Daniels CM, Ong SE & Leung AK (2015) The promise of proteomics for the study of ADP-ribosylation. Mol Cell 58, 911–924.
21 Matic I, Ahel I & Hay RT (2012) Reanalysis of phosphoproteomics data uncovers ADP-ribosylation sites. Nat Methods 9, 771–772.
22 Juarez-Salinas H, Levi V, Jacobson EL & Jacobson MK (1982) Poly(ADP-ribose) has a branched structure in vivo. J Biol Chem 257, 607–609.
23 D’Amours D, Desnoyers S, D’Silva I & Poirier GG (1999) Poly(ADP-ribose)lation reactions in the regulation of nuclear functions. Biochem J 342, 249–268.
ENPP1 processes protein ADP-ribosylation in vitro

by liquid chromatography-tandem mass spectrometry. J Proteome Res 12, 1868–1880.

38 Bollen M, Gijsbers R, Ceulemans H, Stalmans W & Stefan C (2000) Nucleotide pyrophosphatases/phosphodiesterases on the move. Crit Rev Biochem Mol Biol 35, 393–432.

39 Stefan C, Jansen S & Bollen M (2005) NPP-type ectophosphodiesterases: unity in diversity. Trends Biochem Sci 30, 542–550.

40 McDermott M, Wakelam MJ & Morris AJ (2004) Phospholipase D. Biochem Cell Biol 82, 225–253.

41 Mildvan AS, Xia Z, Azurmendi HF, Saraswat V, Legler PM, Massiah MA, Gabelli SB, Bianchet MA, Kang LW & Amzel LM (2005) Structures and mechanisms of Nudix hydrolases. Arch Biochem Biophys 433, 129–143.

42 Kishore BK, Isaac J, Fausther M, Tripp SR, Shi H, Gill PS, Braun N, Zimmermann H, Sévigny J & Robson SC (2005) Expression of NTPDase1 and NTPDase2 in murine kidney: relevance to regulation of P2 receptor signaling. Am J Physiol Renal Physiol 288, 1032–1043.

43 Gijsbers R, Ceulemans H, Stalmans W & Bollen M (2001) Structural and catalytic similarities between nucleotide pyrophosphatases/phosphodiesterases and alkaline phosphatases. J Biol Chem 276, 1361–1368.

44 Cimpean A, Stefan C, Gijsbers R, Stalmans W & Bollen M (2004) Substrate-specifying determinants of the nucleotide pyrophosphatases/pyrophosphodiesterases NPP1 and NPP2. Biochem J 381, 71–77.

45 Gijsbers R, Aoki J, Arai H & Bollen M (2003) The hydrolysis of lysophospholipids and nucleotides by autotaxin (NPP2) involves a single catalytic site. FEBS Lett 538, 60–64.

46 Yano T, Funakoshi I & Yamashina I (1985) Purification and properties of nucleotide pyrophosphatase from human placenta. J Biochem 98, 1097–1107.

47 Hawley DM, Schulz AR & Hodes ME (1984) A comparative kinetic analysis of six substrates widely used for the detection and quantitation of phosphodiesterase I. Enzyme 32, 105–109.

48 Kato K, Nishimatsu H, Mihara E, Ishitani R, Takagi J, Aoki J & Nureki O (2012) Expression, purification, crystallization and preliminary X-ray crystallographic analysis of Enpp1. Acta Crystallogr Sect F Struct Biol Cryst Commun 68 (Pt 7), 778–782.

49 Kato K, Nishimatsu H, Okudaira S, Mihara E, Ishitani R, Takagi J, Aoki J & Nureki O (2012) Crystal structure of Enpp1, an extracellular glycoprotein involved in bone mineralization and insulin signaling. Proc Natl Acad Sci USA 109, 16876–16881.

50 Risseeuw B, Haag F, Boyer O, Koch-Nolte F & Adriouch S (2015) ADP-ribosylation of P2X7: a matter of life and death for regulatory T cells and natural
killer T cells. Curr Top Microbiol Immunol 384, 107–126.

51 Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV & Mann M (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834–840.

52 Nitschke Y & Rutsch F (2012) Genetics in arterial calcification: lessons learned from rare diseases. Trends Cardiovasc Med 22, 145–149.

53 Okawa A, Nakamura I, Goto S, Moriya H, Nakamura Y & Ikegawa S (1998) Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet 19, 271–273.

54 Brachet C, Mansbach AL, Clerckx A, Deltenre P & Heinrichs C (2014) Hearing loss is part of the clinical picture of ENPP1 loss of function mutation. Horm Res Paediatr 81, 63–66.

55 Hessle L, Johnson KA, Anderson HC, Narisawa S, Sali A, Goding JW, Terkeltaub R & Millan JL (2002) Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci USA 99, 9445–9449.

56 Chow WY, Rajan R, Muller KH, Reid DG, Skepper JN, Wong WC, Brooks RA, Green M, Bihan D, Farndale RW et al. (2014) NMR spectroscopy of native and in vitro tissues implicates polyADP ribose in biomineralization. Science 344, 742–746.

57 Krukenberg KA, Kim S, Tan ES, Maliga Z & Mitchison TJ (2015) Extracellular poly(ADP-ribose) is a pro-inflammatory signal for macrophages. Chem Biol 22, 446–452.

58 Zhang Y, Wang J, Ding M & Yu Y (2013) Site-specific characterization of the Asp- and Glu-ADP-ribosylated proteome. Nat Methods 10, 981–984.

59 Berrow NS, Alderton D, Sainsbury S, Nettleship J, Assenberg R, Rahman N, Stuart DI & Owens RJ (2007) A versatile ligation-independent cloning method suitable for high-throughput expression screening applications. Nucleic Acids Res 35, e45.

60 Nettleship JE, Rahman-Huq N & Owens RJ (2009) The production of glycoproteins by transient expression in Mammalian cells. Methods Mol Biol 498, 245–263.

61 Nettleship JE, Watson PJ, Rahman-Huq N, Fairall L, Posner MG, Upadhyay A, Reddivari Y, Chamberlain JM, Kolstoe SE, Bagby S et al. (2015) Transient expression in HEK 293 cells: an alternative to E. coli for the production of secreted and intracellular mammalian proteins. Methods Mol Biol 1258, 209–222.

62 Mueller-Dieckmann C, Scheuermann T, Wursthorn K, Schröder J, Haag F, Schulz GE & Koch-Nolte F (2002) Expression, purification, crystallization and preliminary X-ray analysis of rat ecto-ADP-ribosyltransferase 2 (ART2.2). Acta Crystallogr D Biol Crystallogr 58 (Pt 7), 1211–1213.